Vitamin D2 Side Effects
Vitamin D2 (ergocalciferol) is generally safe at recommended doses, with hypercalcemia being the primary side effect of concern when excessive dosing occurs 1.
Primary Side Effect: Hypercalcemia
The main adverse effect of ergocalciferol is hypercalcemia (elevated blood calcium levels), which occurs with vitamin D toxicity 1. This is the key safety concern that requires monitoring, particularly when using higher therapeutic doses.
Clinical Context for Safety
The evidence demonstrates a remarkably wide safety margin for ergocalciferol:
- Daily doses up to 10,000 IU have been administered to patients with advanced CKD for over 1 year with no evidence of toxicity 2, 3
- The recommended upper limit in normal individuals is 2,000 IU/day, though this provides a substantial safety buffer 3
- One case report documented a patient who inadvertently took 150,000 IU daily for 28 years without developing toxicity 4
The development of hypercalcemia serves as evidence of excessive dosing 2. This makes calcium monitoring the practical safeguard when using ergocalciferol therapeutically.
Contraindications and Special Populations
Ergocalciferol is contraindicated in patients with 1:
- Pre-existing hypercalcemia
- Malabsorption syndrome
- Abnormal sensitivity to vitamin D effects
- Hypervitaminosis D
Critical Warning for Infants
Hypersensitivity to vitamin D may cause idiopathic hypercalcemia in infants, requiring strict restriction of vitamin D in these children 1. This represents a specific vulnerable population requiring heightened caution.
Secondary Considerations
Kidney-Related Effects
In large trials, ergocalciferol showed:
- A small increase in kidney stones (2 more per 1,000 patients) 5
- No significant effect on kidney disease overall 5
These effects were modest and occurred in the context of large population studies.
Comparative Efficacy Note
While not a "side effect" per se, ergocalciferol (D2) is less effective than cholecalciferol (D3) at raising total 25(OH)D levels 6. When D2 is given, it increases 25(OH)D2 but frequently reduces 25(OH)D3 levels, resulting in lower overall vitamin D status improvement compared to D3 6. This is clinically relevant when choosing between formulations.
Monitoring Recommendations
When using therapeutic doses of ergocalciferol:
- Monitor serum calcium levels to detect hypercalcemia early
- In children receiving higher doses, monitor both 25(OH)D and calcium levels carefully 2
- Watch for symptoms of hypercalcemia: decreased appetite, weight loss, weakness, or altered mental status 7
Practical Safety Summary
Hypercalcemia is the primary concern with ergocalciferol, but toxicity is rare at recommended doses. The standard treatment regimens (50,000 IU weekly for deficiency correction) have an excellent safety profile when calcium is monitored 3. Even daily doses of 10,000 IU have been used safely in CKD patients for extended periods 2, 3.
The key is recognizing that hypercalcemia itself signals excessive dosing, making it both the main side effect and the primary monitoring parameter for safe ergocalciferol use.